Table 3. a FAM84B gene amplification in CRPCs.
| Dataset | PC type | Casesb | Upregulationc (%) | Ref |
|---|---|---|---|---|
| Barbieri et al | Primary PC | 109 | 0.9% (1/109) | Nat Genet 44, 685–9, 2012 |
| Hieronymus et al | Primary PC | 104 | 2% (2/104) | PNAS 111, 11139–44, 2014 |
| Taylor et al | Primary PC | 333 | 7% (23/333) | Cancer Cell 18, 11–22, 2010 |
| Total | 546 | 4.8% (26/546) | ||
| Kumar et al | mCRPCc | 149 | 30% (44/149) | Nat Med 22, 369–28, 16 |
| Robinson et al | mCRPC | 150 | 13% (20/150) | Cell 161, 1215–28, 2015 |
| Grasso et al | mCRPC | 61 | 16% (10/61) | Nature 487, 239–43, 2012 |
| Beltran et al | mCRPC | 107 | 44% (47/107) | Nat Med 22, 298–305, 16 |
| Total | 467 | 26% (121/467)* |
a: data were extracted from cBioPortal.
b: number of cases.
c: metastatic castration resistant prostate cancer.
*p < 0.0001 in comparison to the average rate of FAM84B gene amplification by Fisher's Exact Test.